Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Children's Oncology Group
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sellas Life Sciences Group
University of Virginia
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Children's Oncology Group
Dana-Farber Cancer Institute
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Children's Oncology Group
Sumitomo Pharma America, Inc.
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
Children's Oncology Group
Fred Hutchinson Cancer Center
Columbia University
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center